Analysts See $-0.15 EPS for CareDx, Inc (CDNA)

March 14, 2018 - By Marguerite Chambers

 Analysts See $ 0.15 EPS for CareDx, Inc (CDNA)
Investors sentiment increased to 1.88 in 2017 Q3. Its up 1.15, from 0.73 in 2017Q2. It is positive, as 5 investors sold CareDx, Inc shares while 3 reduced holdings. 8 funds opened positions while 7 raised stakes. 6.43 million shares or 0.83% more from 6.38 million shares in 2017Q2 were reported.
Private Wealth Prtnrs Limited Liability Co invested in 235,000 shares. Teton Advsr invested in 14,000 shares. Morgan Stanley has 0% invested in CareDx, Inc (NASDAQ:CDNA) for 700 shares. Trellus Mngmt Co Limited Liability Company holds 0.14% or 27,156 shares. Northern Trust Corp reported 31,648 shares. Wells Fargo Mn, California-based fund reported 1,139 shares. Next Century Growth Limited reported 497,260 shares. Gagnon Ltd Liability holds 2.68% or 3,536 shares in its portfolio. Tpg Grp Inc (Sbs) Advsr reported 174,378 shares or 0.01% of all its holdings. Moreover, Cambridge Advsrs has 0% invested in CareDx, Inc (NASDAQ:CDNA) for 28,575 shares. Paragon Paragon Ii Joint Venture reported 1.27M shares stake. Vanguard Gru holds 315,925 shares or 0% of its portfolio. California Public Employees Retirement owns 175,000 shares. Spark Invest Management Ltd Company invested in 89,600 shares. Gagnon Secs Ltd holds 2.87% of its portfolio in CareDx, Inc (NASDAQ:CDNA) for 2.17 million shares.

Analysts expect CareDx, Inc (NASDAQ:CDNA) to report $-0.15 EPS on March, 22 after the close.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.15 EPS. After having $-0.17 EPS previously, CareDx, Inc’s analysts see -11.76 % EPS growth. The stock decreased 0.52% or $0.03 during the last trading session, reaching $5.72. About 28,720 shares traded. CareDx, Inc (NASDAQ:CDNA) has declined 74.10% since March 14, 2017 and is downtrending. It has underperformed by 90.80% the S&P500.

CareDx, Inc (NASDAQ:CDNA) Ratings Coverage

Among 5 analysts covering CareDx (NASDAQ:CDNA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CareDx had 10 analyst reports since September 25, 2015 according to SRatingsIntel. Raymond James downgraded the shares of CDNA in report on Monday, September 28 to “Market Perform” rating. Craig Hallum initiated the stock with “Buy” rating in Friday, September 25 report. The firm has “Buy” rating given on Monday, January 8 by Piper Jaffray. On Wednesday, September 27 the stock rating was upgraded by Raymond James to “Outperform”. The stock of CareDx, Inc (NASDAQ:CDNA) earned “Buy” rating by H.C. Wainwright on Wednesday, January 31. On Sunday, September 24 the stock rating was maintained by Piper Jaffray with “Buy”. As per Tuesday, June 14, the company rating was maintained by Mizuho. The firm earned “Buy” rating on Monday, October 9 by Craig Hallum.

CareDx, Inc., together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company has market cap of $163.61 million. The firm operates through two divisions, CareDx and Olerup. It currently has negative earnings. The Company’s commercialized testing solution includes the AlloMap heart transplant molecular test , a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection.

More important recent CareDx, Inc (NASDAQ:CDNA) news were published by: which released: “CareDx to Participate in Upcoming Investor Conferences” on February 07, 2018, also published article titled: “CareDx to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on …”, published: “CareDx Inc.” on September 27, 2017. More interesting news about CareDx, Inc (NASDAQ:CDNA) was released by: and their article: “CareDx to Refinance Debt with Perceptive Advisors” with publication date: March 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: